Announcement • May 22
Johnson Pharmacare Limited to Report Q4, 2026 Results on May 27, 2026 Johnson Pharmacare Limited announced that they will report Q4, 2026 results on May 27, 2026 Announcement • Feb 13
Johnson Pharmacare Limited Appoints Parul Agrawal as an Additional Non-Executive & Independent Director of the Company, Effective February 13, 2026 Johnson Pharmacare Limited, at its board meeting held on 13 February, 2026, appointed Parul Agrawal as an Additional Non-Executive & Independent Director of the Company with effect from 13th February, 2026. Date of birth is July 21, 1986. Announcement • Feb 05
Johnson Pharmacare Limited to Report Q3, 2026 Results on Feb 12, 2026 Johnson Pharmacare Limited announced that they will report Q3, 2026 results on Feb 12, 2026 Announcement • Nov 13
Johnson Pharmacare Limited to Report Q2, 2026 Results on Nov 14, 2025 Johnson Pharmacare Limited announced that they will report Q2, 2026 results on Nov 14, 2025 Announcement • Aug 25
Johnson Pharmacare Limited, Annual General Meeting, Sep 25, 2025 Johnson Pharmacare Limited, Annual General Meeting, Sep 25, 2025, at 15:00 Indian Standard Time. Announcement • Jul 16
Johnson Pharmacare Limited to Report Q1, 2026 Results on Jul 23, 2025 Johnson Pharmacare Limited announced that they will report Q1, 2026 results at 12:15 PM, Indian Standard Time on Jul 23, 2025 Announcement • May 13
Johnson Pharmacare Limited to Report Q4, 2025 Results on May 23, 2025 Johnson Pharmacare Limited announced that they will report Q4, 2025 results on May 23, 2025 Announcement • Jan 21
Johnson Pharmacare Limited to Report Q4, 2025 Results on Jan 31, 2025 Johnson Pharmacare Limited announced that they will report Q4, 2025 results on Jan 31, 2025 Announcement • Oct 15
Johnson Pharmacare Limited to Report Q2, 2025 Results on Nov 13, 2024 Johnson Pharmacare Limited announced that they will report Q2, 2025 results on Nov 13, 2024 Announcement • Sep 05
Johnson Pharmacare Limited, Annual General Meeting, Sep 28, 2024 Johnson Pharmacare Limited, Annual General Meeting, Sep 28, 2024. Announcement • Jul 25
Johnson Pharmacare Limited to Report Q1, 2025 Results on Aug 01, 2024 Johnson Pharmacare Limited announced that they will report Q1, 2025 results on Aug 01, 2024 Announcement • May 18
Johnson Pharmacare Limited to Report Q4, 2024 Results on May 25, 2024 Johnson Pharmacare Limited announced that they will report Q4, 2024 results on May 25, 2024 Reported Earnings • Jan 23
Third quarter 2024 earnings released Third quarter 2024 results: Net loss: ₹46.0k (loss narrowed 100% from 3Q 2023). Announcement • Jan 17
Johnson Pharmacare Limited to Report Q3, 2024 Results on Jan 22, 2024 Johnson Pharmacare Limited announced that they will report Q3, 2024 results on Jan 22, 2024 Reported Earnings • Nov 03
First half 2024 earnings released First half 2024 results: Net loss: ₹966.0k (down 127% from profit in 1H 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 122 percentage points per year, which is a significant difference in performance. Announcement • Oct 28
Johnson Pharmacare Limited to Report Q2, 2024 Results on Nov 01, 2023 Johnson Pharmacare Limited announced that they will report Q2, 2024 results on Nov 01, 2023 Announcement • Sep 07
Johnson Pharmacare Limited, Annual General Meeting, Sep 28, 2023 Johnson Pharmacare Limited, Annual General Meeting, Sep 28, 2023, at 13:00 Indian Standard Time. Agenda: To receive, consider and adopt the financial Statement for the year ended on 31 March, 2023 and the Reports of the Board of Directors and the Auditors thereon; to appoint a Director in place of Mr. RAMANLAL TRIVEDI (DIN-01658705) who retires by rotation and being eligible, offers him-self for re-appointment; to reappoint statutory auditors and fix their remuneratio; and to consider other business matters. New Risk • Aug 06
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 9.3% per year over the past 5 years. Revenue is less than US$1m (₹10m revenue, or US$123k). Market cap is less than US$10m (₹253.0m market cap, or US$3.06m). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Announcement • Aug 04
Johnson Pharmacare Limited to Report Q1, 2024 Results on Aug 10, 2023 Johnson Pharmacare Limited announced that they will report Q1, 2024 results on Aug 10, 2023 Buying Opportunity • Apr 17
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 17%. The fair value is estimated to be ₹0.69, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 69% over the last 3 years. Meanwhile, the company became loss making. Announcement • Jan 28
Johnson Pharmacare Limited to Report Q3, 2023 Results on Feb 02, 2023 Johnson Pharmacare Limited announced that they will report Q3, 2023 results on Feb 02, 2023 Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Non-Executive Independent Director Manisha Patel was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Buying Opportunity • Nov 07
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 5.0%. The fair value is estimated to be ₹0.97, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Announcement • Nov 04
Johnson Pharmacare Limited to Report Q2, 2023 Results on Nov 09, 2022 Johnson Pharmacare Limited announced that they will report Q2, 2023 results at 3:30 PM, Indian Standard Time on Nov 09, 2022 Announcement • Sep 07
Johnson Pharmacare Limited, Annual General Meeting, Sep 27, 2022 Johnson Pharmacare Limited, Annual General Meeting, Sep 27, 2022, at 10:00 Indian Standard Time. Agenda: To receive, consider and adopt the financial Statement for the year ended on 31 March, 2022 and the Reports of the Board of Directors and the Auditors thereon;to appoint a Director in place of Mr. RAMANLALTRIVEDI (DIN01658705) who retires by rotation and being eligible, offers himself for reappointment;and to discuss other matters. Board Change • Aug 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Non-Executive Independent Director Manisha Patel was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Jul 07
Johnson Pharmacare Limited to Report Q1, 2023 Results on Jul 25, 2022 Johnson Pharmacare Limited announced that they will report Q1, 2023 results at 12:15 PM, Indian Standard Time on Jul 25, 2022 Board Change • Jul 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Non-Executive Independent Director Manisha Patel was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • May 20
Johnson Pharmacare Limited to Report Q4, 2022 Results on May 25, 2022 Johnson Pharmacare Limited announced that they will report Q4, 2022 results on May 25, 2022 Valuation Update With 7 Day Price Move • Dec 09
Investor sentiment improved over the past week After last week's 15% share price gain to ₹6.04, the stock trades at a trailing P/E ratio of 56.4x. Average trailing P/E is 23x in the Trade Distributors industry in India. Total returns to shareholders of 100% over the past year. Valuation Update With 7 Day Price Move • Sep 23
Investor sentiment deteriorated over the past week After last week's 22% share price decline to ₹3.43, the stock trades at a trailing P/E ratio of 76.3x. Average trailing P/E is 29x in the Trade Distributors industry in India. Total returns to shareholders of 23% over the past three years. Valuation Update With 7 Day Price Move • Aug 18
Investor sentiment deteriorated over the past week After last week's 22% share price decline to ₹2.85, the stock trades at a trailing P/E ratio of 69x. Average trailing P/E is 35x in the Trade Distributors industry in India. Total loss to shareholders of 10% over the past year. Announcement • Feb 01
Sun And Shine Worldwide Limited to Report Q4, 2020 Results on Feb 09, 2021 Sun And Shine Worldwide Limited announced that they will report Q4, 2020 results on Feb 09, 2021 Is New 90 Day High Low • Dec 31
New 90-day low: ₹2.63 The company is down 8.0% from its price of ₹2.85 on 01 October 2020. The Indian market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Trade Distributors industry, which is up 44% over the same period. Is New 90 Day High Low • Dec 15
New 90-day high: ₹3.17 The company is up 6.0% from its price of ₹3.00 on 16 September 2020. The Indian market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Trade Distributors industry, which is up 37% over the same period.